Publication | Open Access

Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study

HepatologyHepatitis CViral HepatitisProof-of-concept StudyAntiviral Drug DevelopmentAntiviral TherapyHepatitisTreatment OptionAntiviral DrugPhase 2Medicine